Janus Henderson Group PLC Buys 101,358 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Janus Henderson Group PLC grew its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 2.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,581,642 shares of the company’s stock after acquiring an additional 101,358 shares during the quarter. Janus Henderson Group PLC owned 0.10% of Mirum Pharmaceuticals worth $189,481,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MIRM. Raymond James Financial Inc. bought a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth $10,611,000. D. E. Shaw & Co. Inc. bought a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth $6,507,000. Marshall Wace LLP boosted its position in shares of Mirum Pharmaceuticals by 641.6% during the fourth quarter. Marshall Wace LLP now owns 175,913 shares of the company’s stock worth $7,274,000 after purchasing an additional 152,191 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Mirum Pharmaceuticals by 10.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,422,729 shares of the company’s stock worth $58,831,000 after purchasing an additional 138,623 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Mirum Pharmaceuticals by 162.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 176,960 shares of the company’s stock worth $7,317,000 after purchasing an additional 109,585 shares in the last quarter.

Wall Street Analysts Forecast Growth

MIRM has been the topic of a number of recent analyst reports. JMP Securities lifted their price target on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a “market outperform” rating in a research report on Friday. HC Wainwright raised their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Finally, Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday, February 27th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $59.00.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 27,279 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the transaction, the chief executive officer now directly owns 138,641 shares in the company, valued at $6,129,318.61. The trade was a 16.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Patrick J. Heron acquired 1,335 shares of the stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average price of $45.57 per share, for a total transaction of $60,835.95. Following the completion of the purchase, the director now directly owns 163,643 shares in the company, valued at $7,457,211.51. The trade was a 0.82% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 92,764 shares of company stock worth $4,109,161. Insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Stock Down 2.1%

Shares of MIRM stock opened at $44.27 on Monday. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.83 and a 1 year high of $54.23. The firm’s fifty day moving average price is $42.82 and its two-hundred day moving average price is $44.30. The firm has a market capitalization of $2.19 billion, a P/E ratio of -21.92 and a beta of 0.95.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $111.59 million for the quarter, compared to analyst estimates of $98.47 million. During the same period in the previous year, the business earned ($0.54) EPS. The company’s revenue was up 61.2% compared to the same quarter last year. On average, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.